Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone
Brief Summary: The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: irinotecan | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: VB-111 + bevacizumab | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: VB-111 + bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2
C: Arm Label: Cediranib 30mg; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Arm Label: Cediranib 20mg + lomustine; Type: OTHER; Interventions: Drug: Cediranib, Drug: Lomustine Chemotherapy | Arm Label: Lomustine and Placebo Cediranib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine Chemotherapy, Drug: Placebo Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 30mg | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Cediranib 20mg + lomustine | Intervention Type: DRUG; Name: Lomustine Chemotherapy; Assigned to Arm(s): Cediranib 20mg + lomustine, Lomustine and Placebo Cediranib | Intervention Type: DRUG; Name: Placebo Cediranib; Assigned to Arm(s): Lomustine and Placebo Cediranib
D: Arm Label: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Arm Label: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: KLH | Arm Label: Group 2 and 2C: Refractory to Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control, Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control

Answer: C